Abstract:Aim: Retinoic acid receptor-related orphan nuclear receptors (RORs) are orphan nuclear receptors that show constitutive activity in the absence of ligands. Among 3 subtypes of RORs, RORc is a promising therapeutic target for the treatment of Th17-mediated autoimmune diseases. Here, we report novel RORc inverse agonists discovered through structure-based drug design. Methods: Based on the structure of compound 8, a previously described agonist of RORa, a series of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives were designed and synthesized. The interaction between the compounds and RORc was detected at molecular level using AlphaScreen assay. The compounds were further examined in 293T cells transfected with RORc and luciferase reporter gene. Thermal stability shift assay was used to evaluate the effects of the compounds on protein stability. Results: A total of 27 derivatives were designed and synthesized. Among them, the compound 22b was identified as the most potent RORc inverse agonist. Its IC 50 values were 2.39 μmol/L in AlphaScreen assay, and 0.82 μmol/L in inhibition of the cell-based luciferase reporter activity. Furthermore, the compound 22b displayed a 120-fold selectivity for RORc over other nuclear receptors. Moreover, a molecular docking study showed that the structure-activity relationship was consistent with the binding mode of compound 22b in RORc. Conclusion: 4-(4-(Benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives are promising candidates for the treatment of Th17-mediated autoimmune diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.

Discovery of N -(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists

Discovery of Novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides As Potent RORγt Inhibitors

Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists

Discovery of N-indanyl Benzamides As Potent RORγt Inverse Agonists

Discovery of Carbazole Carboxamides As Novel RORγt Inverse Agonists.

Discovery of Aryl-Substituted Indole and Indoline Derivatives As RORγt Agonists

Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.

From RORγt Agonist to Two Types of RORγt Inverse Agonists.

Discovery of Biaryl Amides As Potent, Orally Bioavailable, and CNS Penetrant RORγt Inhibitors.

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORγt agonists.

Discovery and Structural Optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1h)-ones As RORc Inverse Agonists

Discovery of tert-amine-based RORγt agonists.

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORt agonists

Discovery of 2H-Chromone-4-one Based Sulfonamide Derivatives As Potent Retinoic Acid Receptor-Related Orphan Receptor Γt Inverse Agonists.

Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists.

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.

Discovery of Tetrahydroquinolines and Benzomorpholines As Novel Potent Ror Gamma T Agonists

Discovery of <i>tert</i>-amine-based RORt agonists

Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new RORγ inhibitors using virtual screening, synthesis and biological evaluation.

Crystallography-guided discovery of carbazole-based retinoic acid-related orphan receptor gamma-t (RORγt) modulators: insights into different protein behaviors with “short” and “long” inverse agonists